Local Vasoconstriction in Postural Tachycardia Syndrome

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Postural Tachycardia Syndrome
Interventions
DRUG

Losartan

Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.

DRUG

Ascorbic Acid (Vitamin C)

Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.

DRUG

Normal Saline

Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.

Trial Locations (1)

10532

New York Medical College/Bradhurst building, Hawthorne

Sponsors
All Listed Sponsors
lead

New York Medical College

OTHER

NCT01210430 - Local Vasoconstriction in Postural Tachycardia Syndrome | Biotech Hunter | Biotech Hunter